Fig. 7
From: The FBXW7-binding sites on FAM83D are potential targets for cancer therapy
FAM83D promotes chemo-resistance in BC. a, FAM83D expression significantly correlated with pathological complete response (pCR) to chemotherapy in ER- breast cancer patients. Significant difference in FAM83D expression between two response groups (left panel) and the predictive value of FAM83D expression for pCR to chemotherapy (right panel) were obtained ROC plotter (https://www.rocplot.org/). b-c, The FAM83D-overexpressed MCF7 cells (b) or FAM83D-silenced MDA-MB-231 cells (c) and their control cells were treated with different concentrations of Doxorubicin (upper), or Docetaxel (lower) for 48 h (n = 6). The cell viability was assessed using CCK8 assay. d, The inhibition rate of 0.5 µg/mL Doxorubicin or 100 nM Docetaxel on FAM83D-overexpressed MCF7 cells and their control cells (n = 6). e, The inhibition rate of 10 µM Doxorubicin, or 20 µM Docetaxel on FAM83D-silenced MDA-MB-231 cells and its control cells (n = 6). Data were presented as mean ± SD. ns: not significant. **: p < 0.01, ***: p < 0.001 based on the Student’s t-test